Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical stage biotech company specializing in INTASYL® siRNA gene silencing technology, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event is scheduled for Thursday, September 5, 2024, at 12 PM EDT.
Robert Bitterman, CEO and Chairman of the Board, will present on behalf of Phio Pharmaceuticals. The presentation will include a live Q&A session. Stakeholders, investors, and interested individuals are invited to register and attend this live event. A replay will be available on the Renmark Financial Communications website.
Phio's INTASYL® technology is designed to enhance the effectiveness of immune cells in killing tumor cells, positioning the company at the forefront of innovative cancer treatments.
Phio Pharmaceuticals (NASDAQ: PHIO), una società biotech in fase clinica specializzata nella tecnologia di silenziamento genico INTASYL® siRNA, ha annunciato la sua partecipazione alla Serie di Roadshow Virtuali Non-Deal di Renmark Financial Communications. L'evento è programmato per giovedì 5 settembre 2024, alle 12 PM EDT.
Robert Bitterman, CEO e Presidente del Consiglio, presenterà a nome di Phio Pharmaceuticals. La presentazione includerà una sessione di domande e risposte dal vivo. Gli stakeholder, gli investitori e le persone interessate sono invitati a registrarsi e partecipare a questo evento dal vivo. Una registrazione sarà disponibile sul sito web di Renmark Financial Communications.
La tecnologia INTASYL® di Phio è progettata per aumentare l'efficacia delle cellule immunitarie nell'eliminare le cellule tumorali, posizionando l'azienda all'avanguardia nei trattamenti innovativi per il cancro.
Phio Pharmaceuticals (NASDAQ: PHIO), una empresa de biotecnología en fase clínica especializada en la tecnología de silenciamiento génico INTASYL® siRNA, ha anunciado su participación en la Serie de Roadshow Virtual No-Acuerdo de Renmark Financial Communications. El evento está programado para jueves, 5 de septiembre de 2024, a las 12 PM EDT.
Robert Bitterman, CEO y Presidente de la Junta, realizará una presentación en nombre de Phio Pharmaceuticals. La presentación incluirá una sesión de preguntas y respuestas en vivo. Se invita a las partes interesadas, inversores e interesados a registrarse y asistir a este evento en vivo. Una repetición estará disponible en el sitio web de Renmark Financial Communications.
La tecnología INTASYL® de Phio está diseñada para mejorar la efectividad de las células inmunitarias en la eliminación de células tumorales, posicionando a la empresa a la vanguardia de los tratamientos innovadores contra el cáncer.
Phio Pharmaceuticals (NASDAQ: PHIO), INTASYL® siRNA 유전자 침묵 기술을 전문으로 하는 임상 단계의 생명공학 회사가 Renmark Financial Communications 가상 비거래 로드쇼 시리즈에 참여한다고 발표했습니다. 본 행사는 2024년 9월 5일 목요일, 오후 12시 EDT에 예정되어 있습니다.
로버트 비터맨, CEO이자 이사회 의장이 Phio Pharmaceuticals를 대신하여 발표할 예정입니다. 발표에는 실시간 질의응답 세션이 포함됩니다. 이해관계자, 투자자 및 관심 있는 개인들이 등록하여 이 라이브 이벤트에 참석하도록 초대됩니다. Renmark Financial Communications 웹사이트에서 재생이 제공될 것입니다.
Phio의 INTASYL® 기술은 면역세포가 종양세포를 죽이는 효율성을 높이도록 설계되어 있으며, 혁신적인 암 치료의 최전선에 회사의 위치를 매립하고 있습니다.
Phio Pharmaceuticals (NASDAQ: PHIO), une société biopharmaceutique en phase clinique spécialisée dans la technologie de silencieux génétique INTASYL® siRNA, a annoncé sa participation à la série de roadshows virtuels non-officiels de Renmark Financial Communications. L'événement est prévu pour le jeudi 5 septembre 2024, à 12h EDT.
Robert Bitterman, PDG et président du conseil, présentera au nom de Phio Pharmaceuticals. La présentation comprendra une session de questions-réponses en direct. Les parties prenantes, les investisseurs et les personnes intéressées sont invités à s'inscrire et à assister à cet événement en direct. Un replay sera disponible sur le site de Renmark Financial Communications.
La technologie INTASYL® de Phio est conçue pour améliorer l'efficacité des cellules immunitaires dans la destruction des cellules tumorales, plaçant ainsi l'entreprise à l'avant-garde des traitements innovants contre le cancer.
Phio Pharmaceuticals (NASDAQ: PHIO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf die INTASYL® siRNA-Gentechnologie spezialisiert ist, hat seine Teilnahme an der Renmark Financial Communications virtuellen Non-Deal Roadshow-Serie bekannt gegeben. Die Veranstaltung findet am Donnerstag, den 5. September 2024, um 12 Uhr EDT statt.
Robert Bitterman, CEO und Vorstandsvorsitzender, wird im Namen von Phio Pharmaceuticals präsentieren. Die Präsentation umfasst eine Live-Q&A-Sitzung. Stakeholder, Investoren und Interessierte sind eingeladen, sich zu registrieren und an dieser Live-Veranstaltung teilzunehmen. Eine Aufzeichnung wird auf der Website von Renmark Financial Communications verfügbar sein.
Die INTASYL®-Technologie von Phio ist darauf ausgelegt, die Effektivität von Immunzellen bei der Bekämpfung von Tumorzellen zu erhöhen und positioniert das Unternehmen an der Spitze innovativer Krebsbehandlungen.
- None.
- None.
Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT
Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Thursday, September 5, 2024, at 12 PM EDT. A replay of the event will be available on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.
Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.
REGISTER HERE: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-phio-KrXIA84uGn
To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary technology, INTASYL, precisely silences virtually any gene in the human genome. In addition to targeting solid tumors, INTASYL can effectively enhance applications in adoptive cell therapy.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221386
FAQ
When is Phio Pharmaceuticals (PHIO) participating in the Renmark Financial Communications Virtual Non-Deal Roadshow?
Who will be presenting for Phio Pharmaceuticals (PHIO) at the Virtual Non-Deal Roadshow?
What is the main focus of Phio Pharmaceuticals' (PHIO) technology?
How can investors attend Phio Pharmaceuticals' (PHIO) Virtual Non-Deal Roadshow presentation?
Will there be a replay available of Phio Pharmaceuticals' (PHIO) Virtual Non-Deal Roadshow presentation?
